Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Up 190.7% in March

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 2,560,000 shares, an increase of 190.7% from the March 15th total of 880,600 shares. Based on an average trading volume of 2,220,000 shares, the short-interest ratio is currently 1.2 days. Currently, 5.3% of the company’s shares are sold short.

Milestone Pharmaceuticals Trading Up 0.3 %

Shares of MIST stock traded up $0.00 during trading hours on Tuesday, hitting $0.83. 783,444 shares of the company’s stock traded hands, compared to its average volume of 761,419. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $2.75. The stock has a market cap of $44.52 million, a PE ratio of -1.03 and a beta of 1.38. The stock’s 50 day simple moving average is $1.66 and its 200 day simple moving average is $1.76.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Cowen lowered shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st. TD Securities cut shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 1st. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th. Finally, TD Cowen downgraded Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Milestone Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $17.00.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Large investors have recently modified their holdings of the company. Jones Financial Companies Lllp grew its position in shares of Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after buying an additional 10,000 shares during the period. Virtu Financial LLC bought a new stake in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $170,000. PVG Asset Management Corp acquired a new position in Milestone Pharmaceuticals during the third quarter worth $46,000. Northern Trust Corp lifted its stake in shares of Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock valued at $137,000 after buying an additional 30,772 shares in the last quarter. Finally, Toronto Dominion Bank bought a new stake in shares of Milestone Pharmaceuticals during the fourth quarter worth about $1,770,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.